Grønningsæter, I.S.; Fredly, H.K.; Gjertsen, B.T.; Hatfield, K.J.; Bruserud, Ø.
Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells 2019, 8, 1229.
https://doi.org/10.3390/cells8101229
AMA Style
Grønningsæter IS, Fredly HK, Gjertsen BT, Hatfield KJ, Bruserud Ø.
Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells. 2019; 8(10):1229.
https://doi.org/10.3390/cells8101229
Chicago/Turabian Style
Grønningsæter, Ida Sofie, Hanne Kristin Fredly, Bjørn Tore Gjertsen, Kimberley Joanne Hatfield, and Øystein Bruserud.
2019. "Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy" Cells 8, no. 10: 1229.
https://doi.org/10.3390/cells8101229
APA Style
Grønningsæter, I. S., Fredly, H. K., Gjertsen, B. T., Hatfield, K. J., & Bruserud, Ø.
(2019). Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells, 8(10), 1229.
https://doi.org/10.3390/cells8101229